Table 4.
Pharmacological features of nicotinic responses in VTA DAergic neurons – antagonists
| Peak | Area | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DHβE (μm) | MEC (μm) | MLA (nm) | DHβE (μm) | MEC (μm) | MLA (nm) | ||||||||
| Type | n | IC50 | Hill | IC50 | Hill | IC50 | Hill | IC50 | Hill | IC50 | Hill | IC50 | Hill |
| ID | 6 | 28 | 1.0 | 1.2 | 1.1 | 17 | 0.6 | 5.3 | 0.9 | 0.9 | 0.9 | 8.2 | 0.4 |
| IID | 6 | 62 | 0.7 | 21 | 0.9 | 130 | 0.7 | 1.2 | 0.6 | 0.4 | 0.6 | 156 | 0.5 |
| IIID | 4 | > 100 | 0.3 | 0.9 | 0.7 | NE | NE | > 100 | 0.4 | 0.1 | 1.2 | NE | NE |
Agonist used for these experiments was 1 mm ACh. All antagonists were coapplied with ACh. NE: no effect.